Market: median 1d +0.0% · breadth 45.2% advancing across 188 names
Data as of — announcements 2026-08-05 · flow 2026-07-31 · prices 2026-08-04
New today: CU6, CY5, KLI, MEM, MGU, NEU. New names versus yesterday's letter, so a continuing story doesn't read as fresh news.
Read these (6)
Today's announcements worth minutes, not seconds — triaged by deterministic rules (a raise, a result into live flow, quantified materiality). The LLM annotates; it never picks the bucket.
67Cu-SAR-bisPSMA 8 GBq dose cohort shows encouraging PSA response (74% PSA25, 63% PSA50) and disease control (81%), with 31% achieving complete/undetectable disease in heavily pre-treated mCRPC patients; safety profile improved versus overall trial population. Data supports continued Cohort Expansion recruitment.
💰PSA25 response rate: 74% (n=14/19) · Complete response/undetectable disease: 31% (n=5/16 at 8 GBq dose) · Disease control rate: 81% (n=13/16) · Median treatment cycles: 2 (range 1–4)
Materiality: Trial efficacy update; insufficient data on patient population size or trials milestones as % of market cap to quantify materiality precisely, but represents positive interim readout on lead candidate in Phase 2 stage
Priced in? Stock +19% over 5d and +5% over 20d into announcement; modest pre-run suggests results partially anticipated but positive efficacy surprise not fully reflected
CY5 has lodged its draft scheme booklet with ASIC and secured North Macedonian regulatory approval, advancing its acquisition by CAML toward shareholder vote in mid-September and implementation in early October 2026. All directors recommend approval, with Kazakhstan clearance awaited under normal government timelines.
💰Acquisition target: Central Asia Metals PLC (CAML) · Transaction structure: Scheme of arrangement (100% acquisition) · North Macedonia clearance: Satisfied · Kazakhstan clearance: Under review
Materiality: Scheme represents 100% equity transaction; lodgement of draft booklet and satisfaction of one merger condition are procedural milestones toward completion, not a revaluation event.
Priced in? Stock +8% over 20d but -4% over 5d; retail inflow ($848k) suggests retail participation ahead of shareholder meeting, but no clear run-up pattern implies mixed sentiment on deal terms.
Killi has commenced a 20,000m drilling campaign at its recently acquired Lodestone iron ore project to grow the existing 110Mt inferred resource along a 25km mineralized corridor, targeting higher-confidence resource classification and metallurgical upside from premium direct-reduction-grade concentrate. The high-purity magnetite product positions the project for potential re-rating if resource size material increases.
💰Drilling program: 20,000m RC & diamond · Existing resource: 110Mt @ 33% mass recovery, 69% Fe · Target corridor: 25km-long mineralized system · Drill target: ~15km infill/extension within 25km system
Materiality: Drilling program targets significant resource extension within a $56m market cap company; success could materially re-rate the project, though drilling is early-stage and outcomes uncertain.
Priced in? Stock +10% over 20d but -7% in last 5d; maiden drill campaign announced post-acquisition (June 2026) so incremental news, but market may have priced in the drilling intent already.
🏔 ~80km near FEX.AX ($212M — 3.78× subject cap) · ~varieskm near GRR.AX ($168M — 3× subject cap) · ~50km near FMG.AX ($56.0B major in district)
deep-dive context available
MEM — European Commercial Roll-out continues with Poland Agreement
Memphasys has secured its third European commercialisation agreement for Felix™ sperm-preparation system in Poland, adding a structured two-year contract (A$350k minimum) with a Warsaw-based IVF distributor. The deal provides a clear pathway from evaluation (Q3 2026) to recurring quarterly orders (Q4 2026 onwards), leveraging Poland's expanding publicly-funded IVF program and TK Biotech's established clinic relationships.
💰Poland contract value: A$350,000 (~€212,000) over 2 years · Market entry: 3rd European market (Italy, UK, Poland) · Revenue timing: Initial evaluation Q3 2026; recurring quarterly orders from Q4 2026 · Partner: TK Biotech (Warsaw-based IVF distributor, est. 2001)
Materiality: A$350k contract = 1.6% of current market cap over 2 years; given company cash position of A$1,179m, financially immaterial but strategically important for proving the in-country partner commercial model across Europe.
Priced in? Stock down 12% over 5 days pre-announcement; no material run-up; incremental milestone in nascent European roll-out rather than a transformational revenue driver.
MGU · $26M — PIRACANJUBA NORTH DELIVERS STRONG REE RESULTS
MGU's third assay batch confirms an expansive, repeatable ionic-adsorption clay REE system across four separate centres at Piracanjuba North, with all 214 holes returning anomalous TREO and strong desorbable NdPr/TbDy payloads (8–69% desorption rates). The lateral extent, consistent geology, and accelerating drill productivity (six consecutive weeks of gains; maiden MRE targeted November) materially de-risk the 116 km² target and support progression toward resource definition.
💰TREO range (best intervals): 2,344–3,066 ppm · MREO range (best intervals): 514–706 ppm · Holes with anomalous TREO: 214 / 214 (100%) · Drilling completed: 5,739 m / 10,000 m target
Materiality: Raise insufficient data; cash ($3.7m) covers ~4–5 months at current burn rate if fully directed to exploration; 10,000 m programme ~50% complete with robust pipeline of pending assays—material to proving out deposit scale before resource estimate.
Priced in? Stock +50% over 20d and +15% over 5d into results; market is repricing on successive positive batches and accelerated drilling cadence—some anticipation evident, but maiden MRE in November remains key inflection ahead.
🏔 near BRE.AX ($1.1B — 43.16× subject cap) · near MEI.AX ($596M — 23.18× subject cap) · near AR3.AX ($25M — 0.98× subject cap)
high-confidence read, materiality quantified
NEU — Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
DAYBUE delivered record quarterly sales (+30% YoY, +24% QoQ) driven by robust STIX adoption, prompting Acadia to raise FY26 guidance and Neuren's royalty guidance to US$53–56m. European approval imminent (Germany Q4 2026) and Japan trial readout due Sep–Nov 2026 provide near-term catalysts for further upside.
💰Q2 2026 DAYBUE net sales: US$125m · Q2 2026 Neuren royalty income: US$12.9m · FY2026 royalty guidance (upgraded): US$53–56m · STIX market penetration: 40% of US patients by Q2 end
Materiality: Royalty guidance upgrade of US$3–2m midpoint (~3% swing) is modest relative to $2.7b market cap; however, Q2 royalty run-rate (~$51–52m annualized) now underpins upgraded FY26 and supports 2028 $700m sales target visibility.
Priced in? Stock +14% over 20 days and +9% over 5 days into this result; strong institutional buying ($5m) suggests market repricing higher growth expectations, but royalty guidance upgrade appears to be validating rather than surprising vs. prior momentum.
PLS — Ceasing to be a substantial holder from MS (ownership notice — flow already captures it)
Broker tape — caveats
Who bought and sold, by broker cohort, on a T+3 lag — spikes vs each stock's own baseline, multi-session streaks, and warnings where 'buying' is likely someone absorbing an exit.